Natco Pharma gets EIR from USFDA for Telangana facility
USFDA had conducted pre-approval inspection at Natco’s facility in Kothur village from March 2-6, 2020
Author
IICT, LAXAI LifeSciences collaborate for key pharma intermediates
The collaboration will primarily focus on umifenovir, remdesivir and a key intermediate of hydroxychloroquine
Alembic Pharma Q4 results: Net profit up 81 per cent to Rs 225 crore
The company had posted a net profit of Rs 124 crore for the corresponding period of the previous fiscal, Alembic Pharmaceuticals…
COVID-19 highlighted vulnerabilities in medical manufacturing supply chain: Fitch
As per the report, as trade war has heightened discussion over the national security implications of manufacturing new…
Indian pharmaceutical firms will play important role in fight against COVID19 pandemic: Ambassador…
India, one of the largest producers of anti-malarial drug hydroxychloroquine, has seen a spurt in demand in recent weeks. India…
MoHFW seeks export ban of anti-TB drugs
Delay in production and receipt of supply may cause acute shortage of these drugs, highlights Union Health Secretary
Aurobindo Pharma gets VAI classification from US regulator for Hyderabad unit
The inspection of Unit IV at Hyderabad, an injectable manufacturing formulation facility of the company, was conducted between…
Alembic gets US FDA nod for generic ophthalmic solution
The company has received tentative approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug…
CDSCO allows import of COVID-19 drugs with less than 60 per cent shelf life
The import of such drugs may be permitted after taking an undertaking from the importers by the port officers of CDSCO that the…
IMF calls on all countries to refrain from putting restrictions on exporting medical supplies
The coronavirus pandemic has infected nearly two million people and killed at least 119,000 globally, according to estimates by…